162792-20-3

Upstream product

• 132662-66-9 1D-5,6-di-O-benzoyl-4-O-benzyl-3-deoxy-1,2-O-isopropylidene-myo-inositol 
• 148888-40-8 1D-4-O-benzyl-3-deoxy-1,2-O-isopropylidene-myo-inositol 
• 100-39-0 benzyl bromide 
• 162792-19-0 (3aR,4R,5S,6R,7aR)-4,5,6-Tris-benzyloxy-2,2-dimethyl-hexahydro-benzo[1,3]dioxole 

Downstream Products

• 162792-21-4 (1R,2R,3R,4S,5R)-3,4,5-Tris-benzyloxy-2-methoxymethoxy-cyclohexanol 
• 197896-23-4 Benzoic acid (1R,2R,3S,4R,6R)-2,3,4-tris-benzyloxy-6-hydroxy-cyclohexyl ester 
• 498554-88-4 1D-4,5,6-tri-O-benzyl-3-deoxy-1-O-p-methoxybenzyl-myo-inositol 
• 197896-29-0 Hexadecanoic acid (R)-2-[benzyloxy-((1R,2R,3S,4R)-2,3,4-tris-benzyloxy-cyclohexyloxy)-phosphoryloxy]-1-hexadecanoyloxymethyl-ethyl ester 
• 197896-28-9 Hexadecanoic acid (R)-2-[benzyloxy-((1R,2R,3S,4R)-2,3,4-tris-benzyloxy-cyclohexyloxy)-phosphanyloxy]-1-hexadecanoyloxymethyl-ethyl ester 
• 197896-24-5 Benzoic acid (1R,2R,3S,4R,6R)-2,3,4-tris-benzyloxy-6-phenoxythiocarbonyloxy-cyclohexyl ester 
• 197896-27-8 Diisopropyl-phosphoramidous acid benzyl ester (1R,2R,3S,4R)-2,3,4-tris-benzyloxy-cyclohexyl ester 
• 197896-25-6 Benzoic acid (1R,2S,3S,4R)-2,3,4-tris-benzyloxy-cyclohexyl ester 
• 162792-26-9 Hexadecanoic acid (R)-2-[benzyloxy-((1R,2R,3S,4R,6R)-2,3,4,6-tetrakis-benzyloxy-cyclohexyloxy)-phosphoryloxy]-1-hexadecanoyloxymethyl-ethyl ester 
• 162792-25-8 Hexadecanoic acid (R)-2-[benzyloxy-((1R,2R,3S,4R,6R)-2,3,4,6-tetrakis-benzyloxy-cyclohexyloxy)-phosphanyloxy]-1-hexadecanoyloxymethyl-ethyl ester 
• 162792-24-7 Diisopropyl-phosphoramidous acid benzyl ester (1R,2R,3S,4R,6R)-2,3,4,6-tetrakis-benzyloxy-cyclohexyl ester 
• 162792-27-0 1D-3-deoxyphosphatidylinositol 
• 162792-22-5 C₃₆H₄₀O₆ 
• 162792-23-6 1D-2,4,5,6-tetra-O-benzyl-3-deoxy-myo-inositol 

Relevant academic research and scientific papers

AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

Disclosed are inhibitors of the serine/threonine kinase Akt, pharmaceutical compositions comprising such inhibitors, and a method of preventing or treating a disease or condition in an animal by the use of such inhibitors. The Akt inhibitors have the form

Synthesis of 1D-3-deoxy- and -2,3-dideoxyphosphatidylinositol

Both 1D-3-deoxy- and -2,3-dideoxyphosphatidylinositol (3 and 18) were synthesized using the regioisomeric mixture of viburnitol 1,2:4,5- and 1,2:5,6- diacetonides as starting material. Selective acidic hydrolysis and subsequent benzylation or deoxygenatio